Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Potassium Phosphates Injection USP, a generic version of Fresenius Kabi's reference drug. The product is used to treat hypophosphatemia and as parenteral nutrition for patients who cannot take oral supplements. According to IQVIA data, the addressable US market for this product was approximately $57 million for the 12-month period ending January 2026. This approval marks the 53rd for the subsidiary, which maintains a high success rate with 53 approvals out of 54 ANDAs filed.

Caplin Point's subsidiary, Caplin Steriles, has received final USFDA approval for Desmopressin Acetate Injection USP, a generic version of Nordic Pharma's DDAVP. The injection is used to treat haemophilia A and diabetes insipidus, targeting a US market valued at approximately $26 million as of December 2025. This approval brings the subsidiary's total USFDA approvals to 52 out of 54 ANDAs filed, showcasing a robust regulatory track record. The company maintains a strong pipeline with over 55 products planned for filing in the next four years.

Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Sodium Phosphates Injection USP, a generic equivalent of Hospira's reference drug. The product is used to treat hypophosphatemia and addresses a US market estimated at approximately $67 million for the 12-month period ending December 2025. This approval brings the subsidiary's total USFDA approvals to 51 out of 54 ANDAs filed, highlighting a strong regulatory track record. The company is actively developing a pipeline of over 55 additional injectable and ophthalmic products for future filings.

Caplin Point Laboratories reported a standalone net profit of ₹87.28 crore for the quarter ended December 31, 2025, marking a 16.8% increase over the ₹74.71 crore reported in the same period last year. Revenue from operations saw a modest growth of 2.1% YoY, reaching ₹189.22 crore. For the nine-month period (9M FY26), standalone net profit rose to ₹275.79 crore from ₹252.99 crore in 9M FY25. The company maintained strong profitability despite a slight sequential dip in revenue and profit compared to Q2 FY26.

Caplin Point Laboratories reported a steady standalone performance for Q3 FY26, with revenue from operations growing 2.15% YoY to ₹189.22 crore. Standalone net profit saw a robust 16.8% YoY increase to ₹87.28 crore, supported by a reduction in total expenses from ₹113.89 crore to ₹103.94 crore. While sequential profit declined from ₹102.59 crore in Q2 FY26, this was largely due to a ₹23.63 crore dividend from a subsidiary recorded in the previous quarter. The company also successfully integrated a ₹0.84 crore impact from new labor code provisions during this period.

Caplin Point Laboratories has received shareholder approval for the appointment of four directors following a postal ballot on January 31, 2026. Mr. Ashok Partheeban and Mr. Vivek Partheeban have been appointed as Vice-Chairmen of the company. Additionally, the board has been strengthened with the appointment of Mrs. Susan Mathew, a retired IAS officer with 36 years of administrative experience, and Dr. K C John as Independent Directors for five-year terms. These appointments are aimed at enhancing corporate governance and strategic oversight.

Caplin Point Laboratories has successfully passed four key resolutions through a postal ballot as of February 3, 2026. Shareholders approved the appointments of Mr. Ashok Partheeban and Mr. Vivek Partheeban as Directors and Vice-Chairmen of the company. Furthermore, the board has been strengthened with the appointment of Dr. K C John and Mrs. Susan Mathew as Non-Executive Independent Directors for five-year terms. All resolutions were passed with the requisite majority, ensuring leadership continuity and enhanced corporate governance.

Caplin Point's subsidiary, Caplin Steriles, has secured final USFDA approval for Methylprednisolone Acetate Injectable Suspension, a generic version of Pfizer's Depo-Medrol. The product addresses a US market valued at approximately $57.4 million for the 12 months ending November 2025. This approval brings the subsidiary's total USFDA approvals to 50 out of 53 filings. The company continues to build a strong pipeline with over 55 injectable and ophthalmic products currently under development for the next four years.

Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) from a leading multinational generic company. The acquired portfolio focuses on Injectable and Ophthalmic products, which had an addressable market of $473.2 million for the 12-month period ending August 2025. This acquisition includes oncology injectables that will be manufactured at the company's new dedicated facility in Kakkalur. The company plans to commercialize these products in the U.S. and progressively expand into Mexico, Canada, the EU, and Brazil.

Caplin Point Laboratories Limited announced the successful completion of an inspection by INVIMA-Colombia at its injectables facility in Puducherry. The inspection took place between December 8th and 12th, 2025. This approval is expected to facilitate the company's expansion into the Latin American market for specialty injectable products. The company already has an INVIMA approved Softgel section at the same site.

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received USFDA approval for Linezolid Injection, 600mg/300mL (2mg/mL) Single-dose Infusion Bags. This is a generic version of Pfizer's ZYVOX. Linezolid Injection is used to treat serious bacterial infections. The US sales for Linezolid Injection were approximately $23 million for the 12-month period ending October 2025, according to IQVIATM (IMS Health).

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received USFDA approval for Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL) Single-dose Infusion Bags. This is a generic version of the Reference Listed Drug (RLD) from Mallinckrodt Pharmaceuticals Ireland Limited. Acetaminophen Injection had US sales of approximately $86 million for the 12-month period ending October 2025. Caplin Steriles has 43 ANDA approvals so far and is working on 40+ injectable and ophthalmic products.